Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jan 15, 2025; 16(1): 92711
Published online Jan 15, 2025. doi: 10.4239/wjd.v16.i1.92711
Published online Jan 15, 2025. doi: 10.4239/wjd.v16.i1.92711
Mizagliflozin ameliorates diabetes induced kidney injury by inhibitor inhibit inflammation and oxidative stress
Zhi-Min Lin, Han-Yuan Gao, Shu-Han Shi, Yue-Ting Li, Department of Nephrology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China
Author contributions: Lin ZM, Gao HY, Shi SH, and Li YT participated in the conceptualization; Gao HY, Shi SH, and Li YT contributed to the data curation, formal analysis, funding acquisition, investigation, and methodology of this manuscript; Shi SH and Li YT were involved in the project administration, resources, software, supervision, validation, visualization, writing - original draft, and writing - review & editing of this study. All authors have read and approve the final manuscript.
Institutional review board statement: Our study received approval from the ethics committee of the Second Affiliated Hospital of Fujian Medical University, No. FJSS20111511.
Institutional animal care and use committee statement: Our study received approval from the Institutional Animal Care and Use Committee, No. FJSS20111511.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The data used to support the findings of this study are included within the article.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yue-Ting Li, MM, Chief Physician, Associate Professor, Department of Nephrology, The Second Affiliated Hospital of Fujian Medical University, No. 34 Zhongshan North Road, Licheng District, Quanzhou 362000, Fujian Province, China.
Received: February 5, 2024
Revised: April 26, 2024
Accepted: October 8, 2024
Published online: January 15, 2025
Processing time: 298 Days and 18.4 Hours
Revised: April 26, 2024
Accepted: October 8, 2024
Published online: January 15, 2025
Processing time: 298 Days and 18.4 Hours
Core Tip
Core Tip: Diabetic nephropathy is a common and serious complication of diabetes, characterized by the accumulation of extracellular matrix in the renal units. Mizagliflozin can improve diabetic nephropathy impairment by inhibiting neural sodium-glucose cotransport protein 1, inflammation, and oxidative stress. Its functions are regarded as positive regulators of inflammation and oxidative stress. These findings offer new treatment methods targeting sodium-glucose cotransport protein 1 inhibitors for diabetic kidney disease.